Obesity Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight’s, “Obesity Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in the Obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including Obesity clinical trials and nonclinical stage products. It also covers the Obesity pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Obesity pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Obesity NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from Obesity Pipeline Insight Report
- DelveInsight’s Obesity Pipeline report depicts a robust space with 100+ active players working to develop 130+ pipeline therapies for Obesity.
- The leading Obesity Companies such as Novartis, Eli Lily &Company, Scohia Pharma, ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Boehringer Ingelheim, Pfizer, and others are evaluating novel Obesity treatment drugs candidate to improve the treatment landscape.
- Promising Obesity Therapies such as VI-0521, THR-4109, PF-06882961, Rosuvastatin, Midazolam, Tirzepatide, Tesofensine, and others.
- The Obesity companies and academics are working to assess challenges and seek opportunities that could influence Obesity R&D. The Obesity pipeline therapies under development are focused on novel approaches to treat/improve Obesity.
To explore more information on the latest breakthroughs in the Obesity Pipeline treatment landscape of the report, click here @ Obesity Pipeline Outlook
Obesity Overview
Obesity can be described as the “New World Syndrome”. Obesity is a multi-factorial disorder, which is often associated with many other significant diseases such as diabetes, hypertension and other cardiovascular diseases, osteoarthritis and certain cancers. The management of obesity will therefore require a comprehensive range of strategies focussing on those with existing weight problems and also on those at high risk of developing obesity. Hence, prevention of obesity during childhood should be considered a priority, as there is a risk of persistence to adulthood. Its prevalence is on continuous rise in all age groups of many of the developed countries in the world. Obesity, in simple terms, may be defined as a state of imbalance between calories ingested versus calories expended which would lead to excessive or abnormal fat accumulation. Obesity is not a single disorder but a heterogeneous group of conditions with multiple causes each of which is ultimately expressed as obese phenotype.
Recent Breakthroughs of Obesity Treatment Landscape
- Tirzepatide also known as LY3298176, (Dual GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of obesity. The dual agonist has also proven to be efficacious in tackling obesity and cardiovascular risk factors associated with T2D.
- Danuglipron (formerly PF 06882961) is an orally administered, small molecule, glucagon-like peptide 1 receptor (GLP 1R) agonist, being developed by Pfizer. The drug is currently in phase 2 stage of development for the treatment of obesity.
- XW003 is a novel, long-lasting glucagon-like peptide-1 (GLP-1) analog developed at Sciwind Biosciences. It has been shown to be safe and well tolerated, and induced dose-dependent weight reductions in early clinical trials. . The drug is currently in phase 2 stage of development for the treatment of obesity.
- Noiiglutide is a glucagon-like peptide-1 (GLP-1) analogue being developed by Jiangsu Hansoh Pharmaceutical for the treatment of obesity. Currently, it is in phase 2 stage of development.
Obesity Emerging Drugs Profile
- Tirzepatide: Eli Lily & Company
- Danuglipron: Pfizer
- XW003: Sciwind Biosciences
- Noiiglutide: Jiangsu Hansoh Pharmaceutical
- MEDI 0382: MedImmune
Request a sample and discover the recent advances in Obesity Ongoing Clinical Trial Analysis and Medications, click here @ Obesity Treatment Landscape
Obesity Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Obesity. The Obesity companies which have their Obesity drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.
Scope of the Obesity Pipeline Insight Report
- Coverage- Global
- Obesity Assessment by Stage and Molecule Type
- Obesity Companies- Novartis, Eli Lily &Company, Scohia Pharma, ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Boehringer Ingelheim, Pfizer, and others are evaluating novel Obesity treatment drugs candidate to improve the treatment landscape.
- Obesity Therapies- VI-0521, THR-4109, PF-06882961, Rosuvastatin, Midazolam, Tirzepatide, Tesofensine, and others
- Obesity Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Table of Content
- Introduction
- Obesity Executive Summary
- Obesity Overview
- Obesity Pipeline Therapeutics
- Obesity Therapeutic Assessment
- Late Stage Products (Phase III)
- Oral Semaglutide: Novo Nordisk
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RZL-012: Raziel Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- DD01: D&D Pharmatech
- Drug profiles in the detailed report…..
- Inactive Obesity Products
- Obesity Key Companies
- Obesity Key Products
- Obesity Unmet Needs
- Obesity Market Drivers
- Obesity Market Barriers
- Obesity Future Perspectives and Conclusion
- Obesity Analyst Views
- Obesity Key Companies
- Appendix
Got Queries? Find out the related information on Obesity Mergers and acquisitions, Obesity Licensing Activities @ Obesity Emerging Drugs, and Recent Trends
Related Reports- Stem Cell Market | Asperger Syndrome Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
